AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
fostemsavir 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antivirals | 5401 | 864953-29-7 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Fostemsavir is a prodrug without significant biochemical or antiviral activity that is hydrolyzed to the active moiety, temsavir, which is an HIV-1 attachment inhibitor. Temsavir binds directly to the gp120 subunit within the HIV-1 envelope glycoprotein gp160 and selectively inhibits the interaction between the virus and cellular CD4 receptors, thereby preventing attachment. Additionally, temsavir can inhibit gp120-dependent post-attachment steps required for viral entry into host cells.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 1.20 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| S (Water solubility) | 250 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,DYRK1B,EIF2AK3,ERBB2,GRK2,ITK,MAP3K21,MAPK7,NTRK2,PDK1,PDK2,PIK3CB,PIK3CD,PRKDC,STK33,SYK,TEK | 25 | |||
| kinase-selectivity-class | AXL,BRAF,CDK9,ERBB2,GRK2,PRKDC | 6 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| July 2, 2020 | FDA | ViiV Healthcare Company | |
| Feb. 4, 2021 | EMA | ViiV HEALTHCARE B.V. |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Virologic failure | 137.23 | 85.31 | 22 | 158 | 3972 | 42617183 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Virologic failure | 97.60 | 76.35 | 14 | 101 | 4938 | 110584246 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J05AX29 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIVIRALS FOR SYSTEMIC USE DIRECT ACTING ANTIVIRALS Other antivirals |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000998 | Antiviral Agents |
| MeSH PA | D019380 | Anti-HIV Agents |
| MeSH PA | D023581 | HIV Fusion Inhibitors |
| MeSH PA | D044966 | Anti-Retroviral Agents |
| CHEBI has role | CHEBI:22587 | antiviral agent |
| CHEBI has role | CHEBI:64946 | anti-HIV agent |
Related Drugs by ATC class:
J05AX Other antivirals 15 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Human immunodeficiency virus I infection | indication | 40780007 | |
| Drug induction of cytochrome p450 CYP3A enzyme | contraindication | 423236002 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 4.66 | CHEMBL | |||||
| Envelope glycoprotein gp160 | Viral envelope protein | INHIBITOR | Kd | 9.08 | SCIENTIFIC LITERATURE | DRUG LABEL | |||
| Envelope glycoprotein gp160 [Cleaved into: Surface protein gp120 | Viral envelope protein | Kd | 9.08 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| D10707 | KEGG_DRUG |
| 97IQ273H4L | UNII |
| 864953-39-9 | SECONDARY_CAS_RN |
| 4039527 | VANDF |
| C4519220 | UMLSCUI |
| CHEBI:755277 | CHEBI |
| CHEMBL3301594 | ChEMBL_ID |
| 11319217 | PUBCHEM_CID |
| DB11796 | DRUGBANK_ID |
| CHEMBL3301598 | ChEMBL_ID |
| CHEMBL3301620 | ChEMBL_ID |
| 10292 | INN_ID |
| C576364 | MESH_SUPPLEMENTAL_RECORD_UI |
| C584152 | MESH_SUPPLEMENTAL_RECORD_UI |
| 11100 | IUPHAR_LIGAND_ID |
| 1105971000202108 | SNOMEDCT_US |
| 890266008 | SNOMEDCT_US |
| 890270000 | SNOMEDCT_US |
| C3712177 | UMLSCUI |
| 336206 | MMSL |
| 38617 | MMSL |
| d09591 | MMSL |
| 018436 | NDDF |
| 018437 | NDDF |
| 11317439 | PUBCHEM_CID |
| 2380373 | RXNORM |
| CHEBI:755300 | CHEBI |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Rukobia | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49702-250 | TABLET, FILM COATED, EXTENDED RELEASE | 600 mg | ORAL | NDA | 27 sections |